JP2003335776A5 - - Google Patents

Download PDF

Info

Publication number
JP2003335776A5
JP2003335776A5 JP2002229532A JP2002229532A JP2003335776A5 JP 2003335776 A5 JP2003335776 A5 JP 2003335776A5 JP 2002229532 A JP2002229532 A JP 2002229532A JP 2002229532 A JP2002229532 A JP 2002229532A JP 2003335776 A5 JP2003335776 A5 JP 2003335776A5
Authority
JP
Japan
Prior art keywords
phenyl
benzoazosin
butoxyethoxy
sulfinyl
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002229532A
Other languages
English (en)
Japanese (ja)
Other versions
JP4316203B2 (ja
JP2003335776A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2003335776A publication Critical patent/JP2003335776A/ja
Publication of JP2003335776A5 publication Critical patent/JP2003335776A5/ja
Application granted granted Critical
Publication of JP4316203B2 publication Critical patent/JP4316203B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002229532A 2001-08-08 2002-08-07 二環性化合物、その製造法および用途 Expired - Lifetime JP4316203B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001240750 2001-08-08
JP2001-240750 2001-08-08
JP2002-66809 2002-03-12
JP2002066809 2002-03-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006355701A Division JP4358851B2 (ja) 2001-08-08 2006-12-28 二環性化合物、その製造法および用途

Publications (3)

Publication Number Publication Date
JP2003335776A JP2003335776A (ja) 2003-11-28
JP2003335776A5 true JP2003335776A5 (enExample) 2007-12-13
JP4316203B2 JP4316203B2 (ja) 2009-08-19

Family

ID=26620186

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2002229532A Expired - Lifetime JP4316203B2 (ja) 2001-08-08 2002-08-07 二環性化合物、その製造法および用途
JP2006355701A Expired - Lifetime JP4358851B2 (ja) 2001-08-08 2006-12-28 二環性化合物、その製造法および用途
JP2009147839A Expired - Lifetime JP5275148B2 (ja) 2001-08-08 2009-06-22 二環性化合物、その製造法および用途
JP2013050937A Pending JP2013136629A (ja) 2001-08-08 2013-03-13 二環性化合物、その製造法および用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006355701A Expired - Lifetime JP4358851B2 (ja) 2001-08-08 2006-12-28 二環性化合物、その製造法および用途
JP2009147839A Expired - Lifetime JP5275148B2 (ja) 2001-08-08 2009-06-22 二環性化合物、その製造法および用途
JP2013050937A Pending JP2013136629A (ja) 2001-08-08 2013-03-13 二環性化合物、その製造法および用途

Country Status (13)

Country Link
US (7) US7371772B2 (enExample)
EP (3) EP1889839B1 (enExample)
JP (4) JP4316203B2 (enExample)
AR (1) AR034985A1 (enExample)
AT (2) ATE460406T1 (enExample)
AU (1) AU2002328092A1 (enExample)
CA (2) CA2459172C (enExample)
DE (1) DE60235632D1 (enExample)
DK (2) DK2206702T3 (enExample)
ES (2) ES2339340T3 (enExample)
PE (1) PE20030329A1 (enExample)
PT (2) PT1423376E (enExample)
WO (1) WO2003014105A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60235632D1 (de) * 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
CA2479071A1 (en) * 2002-03-12 2003-09-18 Hiroyuki Tawada Process for producing optically active sulfoxide derivative
WO2004069833A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 縮環ピリジン誘導体、その製造法および用途
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
US20060178359A1 (en) * 2003-02-07 2006-08-10 Mitsuru Shiraishi Tricyclic compound, process for producing the same, and use
JPWO2005089716A1 (ja) * 2004-03-24 2008-01-31 武田薬品工業株式会社 高含量化製剤
JP5057779B2 (ja) * 2004-03-24 2012-10-24 武田薬品工業株式会社 エマルション安定化製剤
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
US20080031942A1 (en) * 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
CA2741060A1 (en) * 2008-10-17 2010-04-22 Invasc Therapeutics, Inc. Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders
PL3133070T3 (pl) 2009-11-27 2020-01-31 Genzyme Corporation Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
US20130023496A1 (en) 2010-04-02 2013-01-24 Randy Tressler Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
SG11201607859SA (en) * 2014-03-21 2016-10-28 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
EP3148538A4 (en) * 2014-06-02 2018-01-17 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
CN106999593A (zh) 2014-09-12 2017-08-01 妥必徕疗治公司 用于纤维化治疗的赛尼克韦罗组合疗法
JP6716568B2 (ja) * 2014-12-23 2020-07-01 トビラ セラピューティクス， インコーポレイテッド セニクリビロックの製造方法及び関連類似体
RU2722641C2 (ru) 2015-02-10 2020-06-02 Тобира Терапьютикс, Инк. Ценикривирок для лечения заболеваний печени и перитонита
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
CA3028151A1 (en) * 2016-06-21 2017-12-28 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
RU2019109019A (ru) 2016-08-31 2020-10-01 Тобира Терапьютикс, Инк. Твердые формы ценикривирок мезилата и способы изготовления твердых форм ценикривирок мезилата
ES2906992T3 (es) * 2016-12-09 2022-04-21 Medshine Discovery Inc Compuesto de bifenilo como antagonista del receptor CCR2/CCR5
BR112019017314A2 (pt) 2017-02-24 2020-04-14 Genfit composições farmacêuticas para terapia de combinação
US11292785B2 (en) 2018-02-02 2022-04-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2020207263A1 (zh) * 2019-04-08 2020-10-15 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
US20230002360A1 (en) * 2019-06-24 2023-01-05 Shenzhen Lingfang Biotech Co.,Ltd Heterocycloalkyl compounds as CCR2 / CCR5 antagonists
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
BR112022023732A2 (pt) * 2020-05-22 2022-12-20 Medshine Discovery Inc Derivado de piridina e sua aplicação
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用
CN118987211B (zh) * 2023-05-22 2025-09-19 无锡瓴方生物医药科技有限公司 一种联合用药物组合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
DE69520360T2 (de) 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
AU9461898A (en) 1997-10-20 1999-05-10 Dainippon Pharmaceutical Co. Ltd. Stable drug composition
WO1999032100A2 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
WO2000010965A2 (en) * 1998-08-20 2000-03-02 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
WO2000037455A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
JP4807687B2 (ja) 1999-04-12 2011-11-02 塩野義製薬株式会社 塩基性疎水性医薬化合物の医薬組成物の製造法
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
EP1211239A4 (en) 1999-09-06 2003-08-06 Takeda Chemical Industries Ltd PROCESSES FOR THE PREPARATION OF 2,3-DIHYDROAZEPINE COMPOUNDS
DE60235632D1 (de) * 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
CA2479071A1 (en) 2002-03-12 2003-09-18 Hiroyuki Tawada Process for producing optically active sulfoxide derivative
JPWO2005089716A1 (ja) * 2004-03-24 2008-01-31 武田薬品工業株式会社 高含量化製剤
JP5057779B2 (ja) * 2004-03-24 2012-10-24 武田薬品工業株式会社 エマルション安定化製剤
US20080031942A1 (en) * 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
US20080108586A1 (en) 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
US20130023496A1 (en) 2010-04-02 2013-01-24 Randy Tressler Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer
SG10201510402WA (en) 2010-11-18 2016-01-28 Univ Yale Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
JP6178788B2 (ja) 2011-06-27 2017-08-09 ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） Ｃｃｒ２アンタゴニストペプチド
JP6391674B2 (ja) 2013-05-15 2018-09-19 トビラ セラピューティクス， インコーポレイテッド セニクリビロック組成物並びにその製造及び使用方法
SG11201607859SA (en) 2014-03-21 2016-10-28 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
JP6716568B2 (ja) 2014-12-23 2020-07-01 トビラ セラピューティクス， インコーポレイテッド セニクリビロックの製造方法及び関連類似体
RU2722641C2 (ru) 2015-02-10 2020-06-02 Тобира Терапьютикс, Инк. Ценикривирок для лечения заболеваний печени и перитонита

Similar Documents

Publication Publication Date Title
JP2003335776A5 (enExample)
JP2004538039A5 (enExample)
JP2005510235A5 (enExample)
JP2008506632A5 (enExample)
JP2010507641A5 (enExample)
JP2003526716A5 (enExample)
ATE435213T1 (de) Substituierte phenyl-sulfamoyl-carboxamide
TWI372066B (en) Pantoprazole multiparticulate formulations
ATE296302T1 (de) 4-(1,3,4-thiadiazolyl-2-yl)-1,4-diazabizyklo- 3.2.2 nonanderivate, ihre herstellung und ihre therapeutische verwendung
ATE290534T1 (de) 4-(oxadiazol-3-yl)-1,4-diazabizyklo(3.2.2)- nonanderivate, ihre herstellung und therapeutische verwendung
PT1663236E (pt) Combinação compreendendo n-(3-metoxi-5-metilpirazin-2-il)-2-(4- [1,3,4-oxadiazol-2-il]fenil)piridina-3-sulfonamida e um bifosfonato
JP2009520682A5 (enExample)
JP2003215047A5 (enExample)
JP2004149545A5 (enExample)
JP2003160581A5 (enExample)
JP2005504847A5 (enExample)
AU2003234796A1 (en) Diimonium salt mixtures, aminium salts mixtures and use thereof
IS8461A (is) 2-(3,4-dímetýlfenýl)-4-{[2-hýdroxý-3'(1H-tetrasól-5-ýl)bífenýl-3-ýl]-hýdrasónó}-5-metýl-2,4-díhýdrópýrasól-3-ónkólín
DE60317675D1 (de) KRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4-i1-(PYRIDIN-2-YLMETHYL)PIPERIDIN-4-YL -1H-INDOL-3-YL -1H-PYRROLE MONO-HYDROCHLORIDE
JP2005536763A5 (enExample)
IS2473B (is) Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess
JP2005005118A5 (enExample)
IS7766A (is) N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf
DE60117131D1 (de) Pyridazinyl phenyl hydrazone nützlich gegen kongestives herzversagen
JP2002277470A5 (enExample)